SciSparc Ltd., a clinical-stage pharmaceutical company, announced on August 14, 2024, that the Jerusalem District Court in Israel has approved AutoMax Motors Ltd.'s request to hold special class meetings of its shareholders to vote on a merger with SciSparc. This development is part of the ongoing process to finalize the previously announced Agreement and Plan of Merger between SciSparc, AutoMax, and SciSparc Merger Sub Ltd. Additionally, SciSparc disclosed an addendum to the Merger Agreement, extending the deadline to complete the merger from August 30, 2024, to November 30, 2024. The company also issued a press release on the same day, providing updates on the merger and including forward-looking statements regarding the completion of the merger and the potential benefits. SciSparc specializes in developing therapies for central nervous system disorders and rare diseases, with a portfolio that includes cannabinoid-based pharmaceuticals.

SciSparc Ltd., a clinical-stage pharmaceutical company, announced on August 14, 2024, that the Jerusalem District Court in Israel has approved AutoMax Motors Ltd.'s request to hold special class meetings of its shareholders to vote on a merger with SciSparc. This development is part of the ongoing process to finalize the previously announced Agreement and Plan of Merger between SciSparc, AutoMax, and SciSparc Merger Sub Ltd. Additionally, SciSparc disclosed an addendum to the Merger Agreement, extending the deadline to complete the merger from August 30, 2024, to November 30, 2024. The company also issued a press release on the same day, providing updates on the merger and including forward-looking statements regarding the completion of the merger and the potential benefits. SciSparc specializes in developing therapies for central nervous system disorders and rare diseases, with a portfolio that includes cannabinoid-based pharmaceuticals.